J Korean Med Sci.  2022 Feb;37(8):e67. 10.3346/jkms.2022.37.e67.

Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic

• Choe PG
• Kim Y
• Chang E
• Kang CK
• Kim NJ
• Cho NH
• Park WB
• Oh Md

• KMID: 2526801
• DOI: http://doi.org/10.3346/jkms.2022.37.e67

Abstract

We investigated the kinetics of the neutralizing antibody responses to the severe acute respiratory syndrome-coronavirus-2 delta variant over the course of 1 year in 16 patients infected at the beginning of the pandemic. In patients with severe disease, neutralizing responses to the delta variant were detectable, albeit at lower levels than responses to the wild type. Neutralizing responses to the delta variant were undetectable, however, in asymptomatic persons. This finding implies that the vaccination strategy for persons with past natural infection should depend on the severity of the previous infection.

Keyword

COVID-19; SARS-CoV-2; Delta Variant; FRNT

Figure

• 

  Fig. 1 Neutralizing antibody responses against SARS-CoV-2/wt and the SARS-CoV-2 B.1.671.2 (Delta) variant in serially collected samples from 12 symptomatic patients and four asymptomatic individuals. (A) FRNT50 titers against SARS-CoV-2/wt in asymptomatic persons. (B) FRNT50 titers against the delta variant in asymptomatic persons. (C) FRNT50 titers against SARS-CoV-2/wt in individuals who had recovered from mild COVID-19. (D) FRNT50 titers against the delta variant in individuals who had recovered from mild COVID-19. (E) FRNT50 titers against SARS-CoV-2/wt in individuals who had recovered from severe COVID-19. (F) FRNT50 titers against the delta variant in individuals who had recovered from severe COVID-19. Titers ≤ 10 were regarded as 10 and dotted lines indicate 1:40 titer.WT = wild type, FRNT = focus reduction neutralization test, SARS-CoV-2 = severe acute respiratory syndrome-coronavirus-2, COVID-19 = coronavirus disease 2019.

Reference

1. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021; 27(7):1131–1133. PMID: 34045737.

2. Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med. 2021; 385(7):664–666. PMID: 34233096.

3. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596(7871):276–280. PMID: 34237773.

4. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021; 184(16):4220–4236.e13. PMID: 34242578.

5. Choe PG, Kang CK, Kim KH, Yi J, Kim ES, Park SW, et al. Persistence of neutralizing antibody response up to 1 year after asymptomatic or symptomatic SARS-CoV-2 infection. J Infect Dis. 2021; 224(6):1097–1099. PMID: 34166506.

6. Choe PG, Kang EK, Lee SY, Oh B, Im D, Lee HY, et al. Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea. Korean J Intern Med. 2020; 35(4):765–770. PMID: 32460457.

7. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021; 385(16):1474–1484. PMID: 34320281.

8. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021; 384(6):533–540. PMID: 33369366.

9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205–1211. PMID: 34002089.

10. Choe PG, Kang CK, Suh HJ, Jung J, Kang E, Lee SY, et al. Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients. Emerg Infect Dis. 2020; 26(10):2484–2487. PMID: 32579877.

11. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021; 385(7):585–594. PMID: 34289274.

12. Anichini G, Terrosi C, Gandolfo C, Gori Savellini G, Fabrizi S, Miceli GB, et al. SARS-CoV-2 antibody response in persons with past natural infection. N Engl J Med. 2021; 385(1):90–92. PMID: 33852796.